Berislav V Zlokovic, MD, PhD

Berislav Zlokovic, MD, PhD is the University Professor, Mary Hayley and Selim K. Zilkha Chair in Alzheimer’s Disease Research, director of the Zilkha Neurogenetic Institute and Professor and Chair of the Department of Physiology & Neuroscience at the Keck School of Medicine of USC. Zlokovic studies the role of brain microcirculation, particularly the blood-brain barrier (BBB) in health and disease in the adult and aging brain. He made major contributions to our understanding of the role of BBB in the pathogenesis and treatment of Alzheimer’s disease (AD) and stroke. Using animal models and studying human brain, his laboratory has shown that dysfunction in the BBB and brain microcirculation can accumulate before neuronal loss and is an early biomarker of human cognitive dysfunction. His group showed that disrupted cross-talk between BBB-associated pericytes and brain capillary endothelial cells within the neurovascular unit leads to neuronal dysfunction in both synapses and neurons. He showed that targeting the BBB cellular and molecular pathways by gene and cell therapy approaches, small molecules and/or biologics can slow down, arrest and/or prevent development of neurodegenerative changes. He has identified genes and receptors at the BBB that regulate brain levels of Alzheimer’s amyloid-beta toxin, which accumulates with aging and in AD. His team has developed new imaging techniques for studying BBB function in animal models and the living human brain. His findings contributed to development of Phase 2/3 clinical trials for AD. He co-discovered with J.H. Griffin vasculoprotective, neuroprotective, and anti-inflammatory activities of activated protein C (APC) in the CNS, including the receptor requirements and downstream signaling pathways. These findings have been translated in successfully completed Ph 1 and Ph 2 trial of 3K3A-APC, a 2nd generation cell-signaling APC analog, in ischemic stroke patients, which led to a Ph 3 efficacy pivotal trial of 3K3A-APC in patients with ischemic stroke.

Current research interests:
• We study humans at genetic risk for AD, use transgenic models, and iPSC-based human models of the BBB to understand how genes that carry risk for sporadic AD (APOE4, PICALM) affect the cerebrovascular system contributing to dementia, and AD onset and progression.
• We are developing gene and cell therapy approaches for AD using i) BBB cell-specific gene delivery; and ii) iPSC-derived human pericytes to influence and protect neuronal and synaptic functions.
• We study APC biologics and mimetic peptides in the white matter stroke, AD and ALS.
• We work on identifying small molecules that influence genes/pathways linked to AD.
• We work on CSF and imaging BBB biomarkers of human cognitive dysfunction.
• We initiated program on BBB molecular signatures (snRNAseq, proteome) in health and disease using transgenic and human models, and human brain tissue.
• Recently, we have initiated studies to understand how gut microbiome influences BBB in relation to neuronal and synaptic functions using transgenic models of AD.

Zlokovic is recognized internationally as a leader in the fields of AD and stroke research. Thomson Reuters and Clarivate Analytics listed Zlokovic as one of “The World’s Most Influential Scientific Minds” for 21 consecutive years (2002-2022) for ranking in 1 % of the most-cited authors in the field of neurosciences and behavioral sciences. He received the MetLife Award for Medical Research for “significant contributions to our understanding of Alzheimer’s disease and for bringing us closer to a cure”, the Potamkin Prize from the American Academy of Neurology in recognition of “outstanding achievements in research on Alzheimer’s and related neurodegenerative diseases”, the Javits Award from the NINDS in recognition of “distinguished record of substantial contributions in a field of neurological sciences”, the MERIT Award from the NIA in recognition of “sustained contribution to aging and leadership and commitment to the field”, and the USC Associates Award for Creativity in Research and Scholarship “the highest honor the university faculty bestows on its members for distinguished intellectual achievements”. He is the University Professor “awarded very selectively by the President based on multi-disciplinary interests and significant accomplishments in several disciplines”. He is fellow of the AAAS, The European Academy of Sciences, and The Dana Alliance for Brain Initiative. He was appointed nominator for the Nobel Prize in Physiology and Medicine for 5 consecutive years (2017-2022). He is an active entrepreneur and inventor. He co-founded ZZ Biotech, a biotechnology company that is developing treatments for stroke and neurological disorders.

• PICALM: Role in the pathogenesis and treatment of Alzheimer vascular blood-brain barrier clearance dysfunction, neuronal dysfunction, and amyloid-beta, tau and neurodegenerative disorders
  NIH · RF1AG076921 · Aug 15, 2022 – Jul 31, 2025 · Role: Principal Investigator
• Understanding Why the Major Susceptibility Gene for Alzheimer's Disease, APOE4, Affects Women More Than Men
  Krueger Settlement · Jan 1, 2022 – Dec 31, 2026 · Role: Principal Investigator
• Cellular and Molecular studies of APOE regulation of Blood-Brain Barrier, Synaptic and Neuronal Functions and Protection Strategies in Mouse Models with and without Alzheimer's Pathology
  Cure Alzheimer's Fund · Jan 1, 2022 – Jun 30, 2024 · Role: Principal Investigator
• Alzheimer's Disease Research Centers
  NIH · P30AG066530 · Sep 1, 2020 – Mar 31, 2030 · Role: Co-Principal Investigator
• Activated protein C mechanisms of brain white matter protection and new therapies for brain white matter ischemic injury
  NIH · R01NS117827 · Jul 15, 2020 – Apr 30, 2026 · Role: Principal Investigator
• BBB Permeability Imaging in CADASIL
  NIH · R01NS114382 · Feb 1, 2020 – Jan 31, 2025 · Role: Co-Investigator
• Molecular Signatures of APOE-mediated Blood-Brain Barrier Dysfunction Causing Neuronal and Synaptic Dysfunction
  Cure Alzheimer's Fund · Jan 1, 2020 – Dec 31, 2023 · Role: Principal Investigator
• Interaction of the microbiome with the blood brain barrier
  Good Ventures Foundation · Oct 8, 2018 – Oct 31, 2025 · Role: Principal Investigator
• Urban Air Pollution and Alzheimer's Disease: Risk, Heterogeneity, and Mechanisms
  NIH · P01AG055367 · Jul 1, 2018 – Jun 30, 2024 · Role: Co-Investigator
• Vascular Contributions To Dementia and Amyloid and Tau Lesions in APOE4
  Alzheimer's Association · Jun 1, 2017 – Jun 30, 2025 · Role: Principal Investigator
• Understanding the role of the perivascular space in cerebral small vessel disease
  Fondation Leducq · Jan 1, 2017 – Dec 31, 2023 · Role: North American Coordinator
• Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's Disease
  NIH · P01AG052350-06 · Sep 30, 2016 – Mar 31, 2027 · Role: Principal Investigator
• The role of pericytes in the aging brain and pathogenesis and treatment of neurodegeneration, and Alzheimer's A-beta and tau pathology
  NIH · RF1AG039452 · Aug 1, 2011 – Jan 31, 2024 · Role: Principal Investigator
• Alzheimer's Abeta, Tau, Apolipoproteins and Blood-brain barrier
  NIH · R01NS034467 · Sep 1, 1995 – Feb 28, 2025 · Role: Principal Investigator

• Blood Test Might Show Early Warning of Alzheimer's
• Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
• Certain cells secrete a substance that may head off Alzheimer's, USC study finds
• Zlokovic receives nearly $25 million to study Alzheimer's disease
• A specific gene could play a major role in reducing brain swelling after stroke
• Blood-brain barrier test may predict dementia
• Healthy blood vessels may be the answer to Alzheimer's prevention
• Stroke drug may also prevent Alzheimer's disease
• A Lapse in the Brain's Security System Might Cause Alzheimer's—And There's a Drug to Help
• USC Alzheimer's researchers find new culprit and potential treatment target for disease
• A biomarker in the brain's circulation system may be Alzheimer's earliest warning
• New research finds vascular damage in mice with ALS contributes to early development of the neurodegenerative disease, while repairing damage delays disease progression
• Absent Aß, Blood-Brain Barrier Breakdown Predicts Cognitive Impairment
• Early Capillary Damage May Predict Dementia

• Corrigendum to “Impaired spine formation and learning in GPCR kinase 2 interacting protein-1 (GIT1) knockout mice” [Brain Res. 1317 (2010) 218-26]. Brain Res. 2026 Sep 01; 1886:150383.. View in PubMed
• Elevated levels of circulating plasma sPDGFRβ in cognitively impaired APOE4 carriers. Geroscience. 2026 Jun; 48(3):3649-3657.. View in PubMed
• PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. Cell. 2026 Feb 05; 189(3):987-992.. View in PubMed
• A Bivalent Protease-Activated Receptor-Derived Peptide Mimics Neuronal Anti-Apoptotic Activity of Activated Protein C. Bioengineering (Basel). 2025 Aug 22; 12(9).. View in PubMed
• Automatic detection of arterial input function for brain DCE-MRI in multi-site cohorts. Magn Reson Med. 2025 Dec; 94(6):2732-2744.. View in PubMed
• Molecular signature and functional properties of human pluripotent stem cell-derived brain pericytes. bioRxiv. 2025 Apr 28.. View in PubMed
• Cerebral hypoperfusion, brain structural integrity, and cognitive impairment in older APOE4 carriers. Geroscience. 2025 06; 47(3):4973-4986.. View in PubMed
• The blood-brain barrier as a treatment target for neurodegenerative disorders. Expert Opin Drug Deliv. 2025 May; 22(5):673-692.. View in PubMed
• Iron chelation by oral deferoxamine treatment decreased brain iron and iron signaling proteins. J Alzheimers Dis. 2025 Feb; 103(4):1180-1190.. View in PubMed
• In vivo neuroprotection in ischemic stroke by activated protein C requires β-arrestin 2. Blood Vessel Thromb Hemost. 2025 Feb; 2(1).. View in PubMed
• Brain repair mechanisms after cell therapy for stroke. Brain. 2024 Oct 03; 147(10):3286-3305.. View in PubMed
• Decreased functional connectivity is associated with increased levels of Cerebral Spinal Fluid soluble-PDGFRβ, a marker of blood brain barrier breakdown, in older adults. Brain Imaging Behav. 2024 Dec; 18(6):1343-1354.. View in PubMed
• A molecular brain atlas reveals cellular shifts during the repair phase of stroke. bioRxiv. 2024 Aug 22.. View in PubMed
• Iron chelation by oral deferoxamine treatment decreased brain iron and iron signaling proteins. bioRxiv. 2024 Aug 17.. View in PubMed
• Editorial Expression of Concern: Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med. 2024 06; 30(6):1792.. View in PubMed
• Neuronally differentiated macula densa cells regulate tissue remodeling and regeneration in the kidney. J Clin Invest. 2024 Apr 10; 134(11).. View in PubMed
• Retraction Note: Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2024 Apr 03; 15(1):2882.. View in PubMed
• Retraction Note: Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat Med. 2024 Apr; 30(4):1215.. View in PubMed
• Retraction Note: Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med. 2024 Apr; 30(4):1214.. View in PubMed
• Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Mol Neurodegener. 2024 Mar 22; 19(1):27.. View in PubMed
• Fluid biomarkers of the neurovascular unit in cerebrovascular disease and vascular cognitive disorders: A systematic review and meta-analysis. Cereb Circ Cogn Behav. 2024; 6:100216.. View in PubMed
• Erratum: “Air Pollution Particulate Matter Exposure and Chronic Cerebral Hypoperfusion and Measures of White Matter Injury in a Murine Model”. Environ Health Perspect. 2024 Feb; 132(2):29001.. View in PubMed
• The liver and muscle secreted HFE2-protein maintains central nervous system blood vessel integrity. Nat Commun. 2024 02 03; 15(1):1037.. View in PubMed
• Author Correction: Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci. 2024 Jan; 27(1):208.. View in PubMed
• Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3. Neuron. 2023 12 20; 111(24):4116.. View in PubMed
• Molecular biomarkers for vascular cognitive impairment and dementia. Nat Rev Neurol. 2023 12; 19(12):737-753.. View in PubMed
• Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging. Neuron. 2023 Oct 04; 111(19):3131-3132.. View in PubMed
• Author Correction: Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2023 Oct 03; 14(1):6151.. View in PubMed
• TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotection upon Ischemic Stroke in Mice. Cell Rep. 2023 Aug 29; 42(8):113050.. View in PubMed
• Magnetic resonance imaging of white matter response to diesel exhaust particles. Res Sq. 2023 Jul 18.. View in PubMed
• Analysis of brain edema in RHAPSODY. Int J Stroke. 2024 01; 19(1):68-75.. View in PubMed
• Author Correction: Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2023 May; 617(7961):E12.. View in PubMed
• Decreased functional connectivity is associated with increased levels of Cerebral Spinal Fluid soluble-PDGFRβ, a marker of blood brain barrier breakdown, in older adults. Res Sq. 2023 Mar 07.. View in PubMed
• Correction: Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier. Mol Neurodegener. 2023 Feb 24; 18(1):14.. View in PubMed
• Characterization of spastic paraplegia in a family with a novel PSEN1 mutation. Brain Commun. 2023; 5(2):fcad030.. View in PubMed
• PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. Cell. 2023 02 16; 186(4):786-802.e28.. View in PubMed
• Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier. Mol Neurodegener. 2023 01 27; 18(1):7.. View in PubMed
• Nutritional metabolism and cerebral bioenergetics in Alzheimer’s disease and related dementias. Alzheimers Dement. 2023 03; 19(3):1041-1066.. View in PubMed
• Corrigendum: Acute ablation of cortical pericytes leads to rapid neurovascular uncoupling. Front Cell Neurosci. 2022; 16:1078919.. View in PubMed
• Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Mol Neurodegener. 2022 Nov 03; 17(1):71.. View in PubMed
• A “multi-omics” analysis of blood-brain barrier and synaptic dysfunction in APOE4 mice. J Exp Med. 2022 11 07; 219(11).. View in PubMed
• Characterization of perivascular space pathology in a rat model of cerebral small vessel disease by in vivo magnetic resonance imaging. J Cereb Blood Flow Metab. 2022 10; 42(10):1813-1826.. View in PubMed
• How the brain regulates its own immune system. Nat Neurosci. 2022 05; 25(5):532-534.. View in PubMed
• Imaging subtle leaks in the blood-brain barrier in the aging human brain: potential pitfalls, challenges, and possible solutions. Geroscience. 2022 06; 44(3):1339-1351.. View in PubMed
• The small HDL particle hypothesis of Alzheimer’s disease. Alzheimers Dement. 2023 02; 19(2):391-404.. View in PubMed
• Prenatal disruption of blood-brain barrier formation via cyclooxygenase activation leads to lifelong brain inflammation. Proc Natl Acad Sci U S A. 2022 04 12; 119(15):e2113310119.. View in PubMed
• 3K3A-Activated Protein C Protects the Blood-Brain Barrier and Neurons From Accelerated Ischemic Injury Caused by Pericyte Deficiency in Mice. Front Neurosci. 2022; 16:841916.. View in PubMed
• A single-cell atlas of the normal and malformed human brain vasculature. Science. 2022 03 04; 375(6584):eabi7377.. View in PubMed
• Blood-brain barrier link to human cognitive impairment and Alzheimer’s Disease. Nat Cardiovasc Res. 2022 Feb; 1(2):108-115.. View in PubMed
• Brain barriers and their potential role in migraine pathophysiology. J Headache Pain. 2022 Jan 26; 23(1):16.. View in PubMed
• Can prehospital “plasma supplement” neutralize the systemic storm in severe trauma? Cell Rep Med. 2021 12 21; 2(12):100481. Zhao Z, Zlokovic BV . . View in PubMed
• Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. J Exp Med. 2022 01 03; 219(1).. View in PubMed
• Air Pollution Particulate Matter Amplifies White Matter Vascular Pathology and Demyelination Caused by Hypoperfusion. Front Immunol. 2021; 12:785519.. View in PubMed
• Microglia have a grip on brain microvasculature. Nat Commun. 2021 09 06; 12(1):5290.. View in PubMed
• Reply to: Rethink the classical view of cerebrospinal fluid production. Nat Rev Neurol. 2021 09; 17(9):590-591.. View in PubMed
• Air Pollution Particulate Matter Exposure and Chronic Cerebral Hypoperfusion and Measures of White Matter Injury in a Murine Model. Environ Health Perspect. 2021 08; 129(8):87006.. View in PubMed
• Editorial for “MRI-Based Investigation of Association Between Cerebrovascular Structural Alteration and White Matter Hyperintensity Induced by High Blood Pressure”. J Magn Reson Imaging. 2021 11; 54(5):1527-1528.. View in PubMed
• On the intersection between systemic infection, brain vascular dysfunction and dementia. Brain. 2021 07 28; 144(6):1629-1631.. View in PubMed
• Author Correction: APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β. Nat Aging. 2021 Jul; 1(7):624.. View in PubMed
• APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β. Nat Aging. 2021 06; 1(6):506-520.. View in PubMed
• Acetylated tau: A missing link between head injury and dementia. Med. 2021 06 11; 2(6):637-639.. View in PubMed
• Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A. J Exp Med. 2021 04 05; 218(4).. View in PubMed
• Investigating the blood-spinal cord barrier in preclinical models: a systematic review of in vivo imaging techniques. Spinal Cord. 2021 Jun; 59(6):596-612.. View in PubMed
• Evidence that blood-CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen. Headache. 2021 Mar; 61(3):536-545.. View in PubMed
• Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation. Front Neurol. 2021; 12:593582.. View in PubMed
• Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults. Brain Behav Immun. 2021 05; 94:299-307.. View in PubMed
• Cranial Suture Regeneration Mitigates Skull and Neurocognitive Defects in Craniosynostosis. Cell. 2021 01 07; 184(1):243-256.e18.. View in PubMed
• Comparison Between Blood-Brain Barrier Water Exchange Rate and Permeability to Gadolinium-Based Contrast Agent in an Elderly Cohort. Front Neurosci. 2020; 14:571480.. View in PubMed
• Endothelial Tip Cell Finds Its Way with Piezo1. Neuron. 2020 10 14; 108(1):5-7.. View in PubMed
• Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid. J Neurosci. 2020 10 28; 40(44):8573-8586.. View in PubMed
• Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimers Dement. 2020 12; 16(12):1714-1733.. View in PubMed
• A Review of Translational Magnetic Resonance Imaging in Human and Rodent Experimental Models of Small Vessel Disease. Transl Stroke Res. 2021 02; 12(1):15-30.. View in PubMed
• Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer’s disease-Opportunities for Therapy. Alzheimers Dement (Amst). 2020; 12(1):e12053.. View in PubMed
• Therapeutic TVs for Crossing Barriers in the Brain. Cell. 2020 07 23; 182(2):267-269.. View in PubMed
• Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. EBioMedicine. 2020 Sep; 59:102883.. View in PubMed
• Correction: Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. PLoS One. 2020; 15(7):e0236379.. View in PubMed
• 3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. Stroke. 2020 07; 51(7):2236-2239.. View in PubMed
• Building vascular roadmaps: A novel toolset for visualizing and annotating whole mouse brain vasculature. Lab Anim (NY). 2020 06; 49(6):175-176.. View in PubMed
• Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. PLoS One. 2020; 15(5):e0232785.. View in PubMed
• APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020 05; 581(7806):71-76.. View in PubMed
• Channelrhodopsin Excitation Contracts Brain Pericytes and Reduces Blood Flow in the Aging Mouse Brain in vivo. Front Aging Neurosci. 2020; 12:108.. View in PubMed
• A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. Alzheimers Dement. 2020 06; 16(6):821-830.. View in PubMed
• Perivascular spaces in the brain: anatomy, physiology and pathology. Nat Rev Neurol. 2020 03; 16(3):137-153.. View in PubMed
• APOE4 Accelerates Development of Dementia After Stroke: Is There a Role for Cerebrovascular Dysfunction? Stroke. 2020 03; 51(3):699-700. Montagne A, Nation DA , Zlokovic BV . . View in PubMed
• Acute Ablation of Cortical Pericytes Leads to Rapid Neurovascular Uncoupling. Front Cell Neurosci. 2020; 14:27.. View in PubMed
• Every-other-day feeding exacerbates inflammation and neuronal deficits in 5XFAD mouse model of Alzheimer’s disease. Neurobiol Dis. 2020 03; 136:104745.. View in PubMed
• Undetectable gadolinium brain retention in individuals with an age-dependent blood-brain barrier breakdown in the hippocampus and mild cognitive impairment. Alzheimers Dement. 2019 12; 15(12):1568-1575.. View in PubMed
• Functional connectivity among brain regions affected in Alzheimer’s disease is associated with CSF TNF-α in APOE4 carriers. Neurobiol Aging. 2020 02; 86:112-122.. View in PubMed
• Special topic section: linkages among cerebrovascular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: The Berlin Manifesto. Int J Stroke. 2019 Sep 22; 1747493019871915.. View in PubMed
• Mitigating Antagonism between Transcription and Proliferation Allows Near-Deterministic Cellular Reprogramming. Cell Stem Cell. 2019 10 03; 25(4):486-500.e9.. View in PubMed
• Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons. JCI Insight. 2019 07 16; 5.. View in PubMed
• Preventing dementia by preventing stroke: The Berlin Manifesto. Alzheimers Dement. 2019 07; 15(7):961-984.. View in PubMed
• Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nat Neurosci. 2019 07; 22(7):1089-1098.. View in PubMed
• Pericyte constriction underlies capillary derecruitment during hyperemia in the setting of arterial stenosis. Am J Physiol Heart Circ Physiol. 2019 08 01; 317(2):H255-H263.. View in PubMed
• Short-term fish oil supplementation applied in presymptomatic stage of Alzheimer’s disease enhances microglial/macrophage barrier and prevents neuritic dystrophy in parietal cortex of 5xFAD mouse model. PLoS One. 2019; 14(5):e0216726.. View in PubMed
• TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotection upon Ischemic Stroke in Mice. Cell Rep. 2019 04 09; 27(2):549-560.e6.. View in PubMed
• Prion Protein Antagonists Rescue Alzheimer’s Amyloid-β-Related Cognitive Deficits. Trends Mol Med. 2019 02; 25(2):74-76.. View in PubMed
• 3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. J Exp Med. 2019 02 04; 216(2):279-293.. View in PubMed
• Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019 02; 25(2):270-276.. View in PubMed
• Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Ann Neurol. 2019 01; 85(1):125-136.. View in PubMed

• Aisen, Paul
• Lyden, Patrick
• Thompson, Paul
• Wang, Danny
• Toga, Arthur
• Sagare, Abhay